Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.
Journal: Journal of neuromuscular diseases
Published: February 06, 2026
Reachable Workspace as a Clinical Outcome for Upper Extremity Function: A Narrative Review.
Journal: Muscle & nerve
Published: March 05, 2025
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
Journal: The Lancet. Neurology
Published: July 19, 2023
Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism.
Journal: Progress in neurobiology
Published: November 16, 2022
Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.
Journal: Cells
Published: January 24, 2022
Meeting report: the 2021 FSHD International Research Congress.
Journal: Skeletal muscle
Published: November 08, 2021
iMyoblasts for ex vivo and in vivo investigations of human myogenesis and disease modeling.
Journal: eLife
Published: May 13, 2021
Lower Ca2+ enhances the K+-induced force depression in normal and HyperKPP mouse muscles.
Journal: The Journal of general physiology
Published: October 08, 2019
Quantitative proteomics identifies proteins that resist translational repression and become dysregulated in ALS-FUS.
Journal: Human molecular genetics
Published: September 17, 2018
Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin.
Journal: Cell reports
Published: December 20, 2017
ALS mutant SOD1 interacts with G3BP1 and affects stress granule dynamics.
Journal: Acta neuropathologica
Published: February 06, 2016
Last Updated: 09/26/2026